THOR MEDICAL ASA [CBOE]
THOR MEDICAL ASA [CBOE]
- NOK (-)
- Real time data - Cboe CH/DK/FI/NO/SE
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: TRMED_NO
ISIN: NO0010597883

Nordic Nanovector to Present at DNB's 11th Annual Nordic Healthcare Conference

  • 66
Nordic Nanovector to Present at DNB's 11th Annual Nordic Healthcare Conference

PR Newswire

OSLO, Norway, Dec. 7, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview via live webcast at DNB's 11th Annual Nordic Healthcare Conference, taking place on 15 December 2020.

Presentations details are as follows:

DNB's 11th Annual Nordic Healthcare Conference
Date: 15 December 2020
Time: 09:50 to 10:10 (CET)

The presentation will be available at the same time at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Presentations.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: [email protected]

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: [email protected]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-to-present-at-dnb-s-11-th--annual-nordic-healthcare-conference,c3250032

 

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-to-present-at-dnbs-11th-annual-nordic-healthcare-conference-301187141.html

SOURCE Nordic Nanovector

PR Newswire
PR Newswire

PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.